pharma · Idiopathic Pulmonary Fibrosis · Prevention of breast cancer in women with a BRCA1 germline mutation
Shanghai Zerun Biotechnology
Shanghai Reinovax Biologics Co.,LTD
Shanghai Zerun Biotechnology trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
936号 Zhangheng Rd, Shanghai 201203, CN HQ
21 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 936号 Zhangheng Rd, Shanghai 201203, CN
- Employees
- 21
- Programs
- 11
- Drugs
- 33
- Patents
- 11
Shanghai Zerun Biotechnology clinical trials
Registry index of 11 ClinicalTrials.gov studies linked to Shanghai Zerun Biotechnology programs — each row shows trial ID, program name, phase, status, and indication.
Shanghai Zerun Biotechnology trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Shanghai Zerun Biotechnology.
-
LTI-03-2001 (RENEW) — Phase 2
Clinical update -
BRCA-P/ABCSG 50 — Phase 3
Clinical update -
EASYlight-NEK — Approved
Clinical update -
ABCSG 45 — Phase 2
Clinical update -
TAMOXIFEN for Breast cancer — Phase 3
Clinical update -
ABCSG 63 — Phase 2
Clinical update -
Nivolumab — Phase 3
Clinical update -
LTI-01 — Phase 2
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2024-512821-10-00CTIS ↗
ABCSG 45
Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)
- 2024-513734-38-00CTIS ↗
BRCA-P/ABCSG 50
Prevention of breast cancer in women with a BRCA1 germline mutation
-
CTIS ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗